LeonaBio Q2 net loss widens on higher R&D spending
LONA•What drove the quarter
- Clinical trial spend — The company said higher R&D expenses were mainly due to increased spending on the ELAINE-3 trial for lasofoxifene.
- Personnel costs — LeonaBio said higher G&A expenses were mainly due to personnel-related expenses and professional service fees.
- Commercial readiness investment — The company said it is investing in CMC, regulatory, and commercial readiness activities ahead of potential approval.
Trial and spending outlook
LeonaBio expects to complete enrollment in its Phase 3 ELAINE-3 trial in 4Q 2026 and to report topline data in 2H 2027.
The company said an update on the timing of its brelgometon Phase 2 trial is expected after ELAINE-3 enrollment is completed.
Q2 loss widens on higher R&D spending
US biopharma firm LeonaBio said its second-quarter net loss widened year over year as research and development spending increased for a cancer trial.
Operating expenses in the quarter nearly tripled, reflecting higher clinical trial and personnel costs.
